Peringatan Keamanan

LD50=128 mg/kg (mouse), side effects include lethargy, rash, fatigue, nausea and myelosuppression.

Pentostatin

DB00552

small molecule approved investigational

Deskripsi

A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.

Struktur Molekul 2D

Berat 268.2691
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 5.7 hours (with a range between 2.6 and 16 hrs)
Volume Distribusi -
Klirens (Clearance) * 68 mL/min/m2

Absorpsi

Not absorbed orally, crosses blood brain barrier.

Metabolisme

Primarily hepatic, but only small amounts are metabolized.

Rute Eliminasi

In man, following a single dose of 4 mg/m2 of pentostatin infused over 5 minutes, approximately 90% of the dose was excreted in the urine as unchanged pentostatin and/or metabolites as measured by adenosine deaminase inhibitory activity.

Interaksi Obat

1188 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Pentostatin.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Pentostatin.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pentostatin.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pentostatin.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Pentostatin.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Pentostatin.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Pentostatin.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Pentostatin.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Pentostatin.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pentostatin.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Pentostatin.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pentostatin.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pentostatin.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Pentostatin.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pentostatin.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pentostatin.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Pentostatin.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Pentostatin.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Pentostatin.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pentostatin.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Pentostatin.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pentostatin.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Pentostatin.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Pentostatin.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pentostatin.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pentostatin.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Pentostatin.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pentostatin.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Pentostatin.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Pentostatin.
Cladribine Pentostatin may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Pentostatin.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Pentostatin.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Pentostatin.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Pentostatin.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Pentostatin.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Pentostatin.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Pentostatin.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Pentostatin.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Pentostatin.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Pentostatin.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Pentostatin.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Pentostatin.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pentostatin.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Pentostatin.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Pentostatin.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Pentostatin.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Pentostatin.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Pentostatin.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Pentostatin.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Pentostatin.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Pentostatin.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Pentostatin.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Pentostatin.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Pentostatin.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Pentostatin.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Pentostatin.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pentostatin.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Pentostatin.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pentostatin.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pentostatin.
Methotrexate The risk or severity of adverse effects can be increased when Pentostatin is combined with Methotrexate.
Carbamazepine The risk or severity of adverse effects can be increased when Pentostatin is combined with Carbamazepine.
Vinblastine The risk or severity of adverse effects can be increased when Pentostatin is combined with Vinblastine.
Fluticasone propionate The risk or severity of adverse effects can be increased when Pentostatin is combined with Fluticasone propionate.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Pentostatin is combined with Fluocinolone acetonide.
Linezolid The risk or severity of adverse effects can be increased when Pentostatin is combined with Linezolid.
Imatinib The risk or severity of adverse effects can be increased when Pentostatin is combined with Imatinib.
Triamcinolone The risk or severity of adverse effects can be increased when Pentostatin is combined with Triamcinolone.
Clofarabine The risk or severity of adverse effects can be increased when Pentostatin is combined with Clofarabine.
Prednisone The risk or severity of adverse effects can be increased when Pentostatin is combined with Prednisone.
Pemetrexed The risk or severity of adverse effects can be increased when Pentostatin is combined with Pemetrexed.
Fludrocortisone The risk or severity of adverse effects can be increased when Pentostatin is combined with Fludrocortisone.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Pentostatin is combined with Mycophenolate mofetil.
Daunorubicin The risk or severity of adverse effects can be increased when Pentostatin is combined with Daunorubicin.
Tretinoin The risk or severity of cardiotoxicity can be increased when Pentostatin is combined with Tretinoin.
Irinotecan The risk or severity of adverse effects can be increased when Pentostatin is combined with Irinotecan.
Methimazole The risk or severity of adverse effects can be increased when Pentostatin is combined with Methimazole.
Etoposide The risk or severity of adverse effects can be increased when Pentostatin is combined with Etoposide.
Sulfasalazine The risk or severity of adverse effects can be increased when Pentostatin is combined with Sulfasalazine.
Dacarbazine The risk or severity of adverse effects can be increased when Pentostatin is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Pentostatin is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Pentostatin is combined with Penicillamine.
Prednisolone The risk or severity of adverse effects can be increased when Pentostatin is combined with Prednisolone.
Sirolimus The risk or severity of adverse effects can be increased when Pentostatin is combined with Sirolimus.
Mechlorethamine The risk or severity of adverse effects can be increased when Pentostatin is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Pentostatin is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Carboplatin.
Methylprednisolone The risk or severity of adverse effects can be increased when Pentostatin is combined with Methylprednisolone.
Dactinomycin The risk or severity of adverse effects can be increased when Pentostatin is combined with Dactinomycin.
Cytarabine The risk or severity of adverse effects can be increased when Pentostatin is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Pentostatin is combined with Azathioprine.
Doxorubicin The risk or severity of adverse effects can be increased when Pentostatin is combined with Doxorubicin.
Hydroxyurea The risk or severity of adverse effects can be increased when Pentostatin is combined with Hydroxyurea.
Busulfan The risk or severity of adverse effects can be increased when Pentostatin is combined with Busulfan.
Mycophenolic acid The risk or severity of adverse effects can be increased when Pentostatin is combined with Mycophenolic acid.
Topotecan The risk or severity of adverse effects can be increased when Pentostatin is combined with Topotecan.
Mercaptopurine The risk or severity of adverse effects can be increased when Pentostatin is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Pentostatin is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Pentostatin is combined with Melphalan.

Target Protein

Adenosine deaminase ADA

Referensi & Sumber

Synthesis reference: Nadji Sourena, "Process for the production of pentostatin aglycone and pentostatin." U.S. Patent US20040181052, issued September 16, 2004.

Contoh Produk & Brand

Produk: 4 • International brands: 0
Produk
  • Nipent
    Injection, powder, lyophilized, for solution • 2 mg/1mL • Intravenous • US • Approved
  • Nipent Pws 10mg/vial
    Powder, for solution • 10 mg / vial • Intravenous • Canada • Approved
  • Pentostatin
    Injection, powder, lyophilized, for solution • 10 mg/5mL • Intravenous • US • Generic • Approved
  • Pentostatin
    Injection, powder, lyophilized, for solution • 2 mg/1mL • Intravenous • US • Generic • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul